Results 291 to 300 of about 274,076 (393)

Anaplastic large cell lymphoma in children and adolescents

British Journal of Haematology, EarlyView.
Summary Anaplastic lymphoma kinase (ALK)‐positive anaplastic large‐cell lymphoma (ALCL) accounts for >95% of ALCL cases in children and adolescents. The first description of ALCL as a CD30‐positive lymphoma in 1985 was followed by the detection of chromosomal translocations involving the ALK gene at chromosome 2p23.
Eric J. Lowe, Wilhelm Woessmann
wiley   +1 more source

Anti‐thymocyte globulin in immune‐mediated cytopenias: A monocentric experience and literature review

British Journal of Haematology, EarlyView.
Anti‐thymocyte globulin in multi‐refractory immune‐mediated cytopenia is an effective treatment, with response rate as high as 65%. Younger patients, presenting with thrombocytopenia or neutropenia, and those with LGL and STAT3 mutations appear to be more likely responsive.
Luca Guarnera, Arooj Ahmed, Carlos Bravo‐Perez, Olisaemeka D. Ogbue, Matteo D'Addona, Zachary Brady, Serhan Unlu, Christopher Haddad, Aashray Mandala, Arda Durmaz, Carmelo Gurnari, Valeria Visconte, Jaroslaw P. Maciejewski   +12 more
wiley   +1 more source

Neutrophil CD64 can be an early predictor for sepsis during febrile neutropenic episodes in children with cancer: a case control study. [PDF]

Ital J Pediatr
Zakaria M, Karam N, Hassan T, Zidan N, Abdelsalam A, Ramadan RA, Rashad MLM, Abdelaziz E, Ramadan A, Ali AA.   +9 more
europepmc   +1 more source

Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies

British Journal of Haematology, EarlyView.
A retrospective analysis of patients with chronic myelomonocytic leukaemia treated with oral decitabine 35 mg + cedazuridine 100 mg suggested favourable outcomes, particularly in higher risk patients. The results provide a rationale for further prospective study of oral decitabine/cedazuridine to identify subgroups of this population who would benefit ...
Michael R. Savona, Olatoyosi Odenike, Gail J. Roboz, Harshad Amin, Amy E. DeZern, Elizabeth A. Griffiths, Kim‐Hien Dao, Amer M. Zeidan, Bhavana Bhatnagar, Rena Buckstein, Brian Leber, Mary‐Margaret Keating, Somedeb Ball, Aram Oganesian, Yuri Sano, Harold N. Keer, Guillermo Garcia‐Manero   +16 more
wiley   +1 more source

Recurrent late-onset neutropenia after ofatumumab treatment in a case of multiple sclerosis. [PDF]

Neurol Res Pract
Chen J, Burmeister T, Frankenstein L, Laumeier I, Siffrin V.   +4 more
europepmc   +1 more source

Copanlisib in combination with rituximab and bendamustine for transplant‐ineligible relapsed/refractory diffuse large B‐cell lymphoma patients: Results from the phase II multicentre FIL Copa‐BR trial from Fondazione Italiana Linfomi (FIL)

British Journal of Haematology, EarlyView.
A phase II, single‐arm, multicentre trial was conducted by Fondazione Italiana Linfomi (FIL) to investigate the combination of copanlisib plus rituximab and bendamustine (copa‐BR) in transplant‐ and chimeric antigen receptor (CAR)‐T‐ineligible relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). Thirty‐seven patients were enrolled.
Mattia Novo, Pio Manlio Mirko Frascione, Alessia Castellino, Luigi Marcheselli, Samantha Deianira Dattoli, Margherita Vannucchi, Delia Rota‐Scalabrini, Alessandra Tucci, Guido Gini, Giuseppe Tarantini, Donato Mannina, Annalisa Arcari, Arcangelo Liso, Elisabetta Scarpa, Dario Marino, Michele Spina, Ausilia Gorgone, Nicola Di Renzo, Salvatrice Mancuso, Luigi Petrucci, Agostino Tafuri, Barbara Botto, Francesca Bonello, Elisa Santambrogio, Umberto Vitolo   +24 more
wiley   +1 more source

Optimal Primary Prophylaxis for Febrile Neutropenia During Neoadjuvant Cisplatin and 5-Fluorouracil Plus Docetaxel for Esophageal Cancer: A Retrospective Cohort Study. [PDF]

Cancer Med
Kumanishi R, Taniguchi H, Nakazawa T, Ogata T, Matsubara Y, Kodama H, Nakata A, Honda K, Masuishi T, Narita Y, Kadowaki S, Ando M, Tajika M, Abe T, Muro K.   +14 more
europepmc   +1 more source

Chronic Neutropenia

Medicine, 1979
D C, Dale, D, Guerry, J R, Wewerka, J M, Bull, M J, Chusid   +4 more
openaire   +2 more sources

The anti‐CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B‐cell lymphomas

British Journal of Haematology, EarlyView.
Follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL) are characterized by a continuous incidence of relapse and increasing resistance to therapy. Novel immunotherapy approaches are needed.
Rahul Lakhotia, Christopher Melani, Stefania Pittaluga, Max J. Gordon, James D. Phelan, Jagan R. Muppidi, Atekelt Tadese, Sarah Evans, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski   +11 more
wiley   +1 more source

The Clinical Safety and Efficacy of Cytarabine and Daunorubicin Liposome (CPX-351) in Acute Myeloid Leukemia Patients: A Systematic Review. [PDF]

Cancer Rep (Hoboken)
Alzahrani AM, Alnuhait MA, Alqahtani T.
europepmc   +1 more source